عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

For 1st Time in Saudi Arabia, Facility for Prosthetics Using 3D Technology

The use of the digital industry in the manufacture of limbs reduces the chance of human errors (Asharq Al-Awsat)
The use of the digital industry in the manufacture of limbs reduces the chance of human errors (Asharq Al-Awsat)
TT
TT

For 1st Time in Saudi Arabia, Facility for Prosthetics Using 3D Technology

The use of the digital industry in the manufacture of limbs reduces the chance of human errors (Asharq Al-Awsat)
The use of the digital industry in the manufacture of limbs reduces the chance of human errors (Asharq Al-Awsat)

Heal-Tec, a Saudi-based medical rehabilitation manufacturing facility, is the first of its kind in Saudi Arabia to manufacture prostheses, prosthetic devices and aids using digital industry that includes scanning and 3D printing.

Co-founded in 2020 by Dr. Hashim AlZain and Eng. Ayman Noori, HealTec is a dedicated B2B healthcare rehabilitation manufacturing facility that enables the local production of medical prosthetics and other devices to serve long-term care and rehabilitation patients.

In remarks to Asharq Al-Awsat, AlZain said that the use of digital industry in the manufacture of prosthetics has many benefits, including accuracy of measurements and speed of response, as it allows the production of accurate and complex parts more and faster than traditional methods, allowing patients to have a quick treatment and recovery.

According to AlZain, previous traditional methods were done either by using gypsum or meter measurements, and depended on the skill of the service provider; thus, human errors were frequent. But the use of this technology has greatly reduced these risks, he underlined.

AlZain noted that the size of the prosthetics market amounted to 3.7 billion Saudi riyals annually. He added that during the next five years, the factory’s share would reach 85 million riyals, to cover approximately 40 percent of the local needs.

Service providers in hospitals and rehabilitation centers usually import all the material from outside the Kingdom, which necessitates a long period of supply. Prosthetics and auxiliary devices may take more than three weeks to be supplied, which causes a backlog in appointments.

HealTec provides its manufacturing services to rehabilitation hospitals and healthcare centers across the Kingdom in record time compared to the traditional means, which rely heavily on imports.

The factory is also able to export prosthetics, devices, and aids to neighboring countries through the King Salman Humanitarian Aid and Relief Center, which enhances the implementation of the Kingdom’s Vision 2030.

Most Viewed

 
 
Varieties

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”